This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CareFusion Provides Update On Voluntary Recall Of Select AirLife™ Respiratory Products





SAN DIEGO, July 2, 2012 /PRNewswire/ -- CareFusion issued the following update regarding its voluntary recall of its Air Life™ Infant Breathing Circuit. The FDA has classified this action as a Class 1 recall.

The company initiated the voluntary recall on May 29. The products subject to the recall were manufactured between June 1, 2010, and Feb. 3, 2012. This action has no effect on the manufacture or distribution of current products.

In May 2012, the company sent an urgent Recall Notification to customers and distributors stating the identified potential risks associated with the Air Life Infant Breathing Circuit. The Y-adapter in affected products could develop cracks during patient use, potentially resulting in a leak in the closed ventilation system and leading to a loss in the intended tidal volume delivered to the patient. A Class I recall is defined as a reasonable probability of serious adverse health consequences or death associated with use of the defective units. To date, there have been no reports of patient harm associated with the affected products.

There is no change to the remediation plans previously announced by the company. In the notification letter, customers were provided lot numbers of affected product codes and asked to destroy any affected products remaining in inventory. This information is available at http://www.carefusion.com/customer-support/alerts-notices/medical-device-recall-for-airlife-infant-breathing-circuit.aspx.

Since the recall was initiated in May, nearly half of the affected customers and distributors have completed the remediation process.

Instructions to customersCustomer inquiries related to this action should be addressed to CareFusion Customer Service at Customer.Experience@carefusion.com

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program: by mail at MedWatch, HF-2, FDA 5600 Fishers Lane, Rockville, MD 20852-9787; by phone at 1-800-332-1088; by fax at 1-800.FDA.0178 or at www.fda.gov/medwatch.

Additional product recall information

CareFusion has posted on its website information regarding the Air Life product recall and other product recalls and alerts. Also today, the company separately filed with the Securities and Exchange Commission a Form 8-K in which the company reported an expected increase to its recall reserve of approximately $7 million for the quarter and fiscal year ended June 30, 2012. This adjustment is primarily related to a voluntary recall affecting the PC unit of certain models of the company's Alaris® infusion pumps. More information can be found on the company's website at http://www.carefusion.com/customer-support/alerts-notices/medical-device-recall-alaris-8015.aspx. About CareFusionCareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, Air Life™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs